

# Johnson & Johnson Reports Q2 2021 Results:

- Strong sales growth of 27.1% to \$23.3 Billion in Second Quarter 2021 with operational growth of 23.0%\* and adjusted operational growth of 23.8%\*
- EPS of \$2.35 increased 72.8% in Second Quarter 2021 and adjusted EPS of \$2.48 increased 48.5%\*
- Company increasing 2021 Full-Year guidance for sales and EPS

New Brunswick, N.J. (July 21, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter. “Our second-quarter results showcase Johnson & Johnson’s diversified portfolio, driven by strong sales and earnings growth across our Medical Device, Consumer Health and Pharmaceutical businesses,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to patients and consumers around the world, in addition to advancing our pipeline with new product launches and regulatory submissions. These accomplishments exemplify our commitment to advancing transformational innovations that improve the health of people and communities everywhere while continuing to deliver long-term value to all of our stakeholders.”

## OVERALL FINANCIAL RESULTS

Q2				
(\$ in Millions, except EPS)	2021	2020	% Change	
Reported Sales	\$ 23,312	\$ 18,336	27.1%	
Net Earnings	6,278	3,626	73.1	
EPS (diluted)	\$ 2.35	\$ 1.36	72.8%	

Q2				
Non-GAAP* (\$ in Millions, except EPS)	2021	2020	% Change	
Operational Sales <sup>1,2</sup>			23.0%	
Adjusted Operational Sales <sup>1,3</sup>			23.8	
Adjusted Net Earnings <sup>1,4</sup>	6,625	4,446	49.0	
Adjusted EPS (diluted) <sup>1,4</sup>	\$ 2.48	\$ 1.67	48.5%	

<sup>1</sup> [Non-GAAP financial measure](#); refer to reconciliations of non-GAAP financial measures included in accompanying schedules

<sup>2</sup> Excludes the impact of translational currency

<sup>3</sup> Excludes the net impact of acquisitions and divestitures and translational currency

<sup>4</sup> Excludes intangible amortization expense and special items

## **REGIONAL SALES RESULTS**

Q2 (\$ in Millions)			% Change			Adjusted Operational <sup>1,3</sup>
	2021	2020	Reported	Operational <sup>1,2</sup>	Currency	
U.S.	\$ 11,919	\$ 9,539	24.9%	24.9	-	25.1
International	11,393	8,797	29.5	20.9	8.6	22.4
Worldwide	\$ 23,312	\$ 18,336	27.1%	23.0	4.1	23.8

<sup>1</sup> [Non-GAAP financial measure](#); refer to reconciliations of non-GAAP financial measures included in accompanying schedules

<sup>2</sup> Excludes the impact of translational currency

<sup>3</sup> Excludes the net impact of acquisitions and divestitures and translational currency

Note: values may have been rounded

## **SEGMENT SALES RESULTS**

Q2 (\$ in Millions)			% Change			Adjusted Operational <sup>1,3</sup>
	2021	2020	Reported	Operational <sup>1,2</sup>	Currency	
Consumer Health	\$ 3,735	\$ 3,296	13.3%	9.2	4.1	10.0
Pharmaceutical	12,599	10,752	17.2	13.6	3.6	14.1
Medical Devices	6,978	4,288	62.7	57.2	5.5	58.7
Worldwide	\$ 23,312	\$ 18,336	27.1%	23.0	4.1	23.8

<sup>1</sup> [Non-GAAP financial measure](#); refer to reconciliations of non-GAAP financial measures included in accompanying schedules

<sup>2</sup> Excludes the impact of translational currency

<sup>3</sup> Excludes the net impact of acquisitions and divestitures and translational currency

Note: values may have been rounded

## **Second Quarter 2021 SEGMENT COMMENTARY:**

### **Consumer Health**

Consumer Health worldwide operational sales, excluding the net impact of acquisitions and divestitures, increased 10.0%\* inclusive of the market recovery from COVID-19 impacts, primarily in skin health/beauty. Sales growth was driven by skin health/beauty products including NEUTROGENA, AVEENO, and OGX; over-the-counter products including ZYRTEC in upper respiratory products, international analgesics, and digestive health products; and BAND-AID® Brand Adhesive Bandages in wound care products.

### **Pharmaceutical**

Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 14.1%\* driven by STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, DARZALEX (daratumumab), for the treatment of multiple myeloma, TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies,

a type of blood or lymph node cancer, and INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults. This growth was partially offset by biosimilar and generic competition, with declines primarily in REMICADE (infliximab), a biologic approved for the treatment of a number of immune-mediated inflammatory diseases.

### **Medical Devices**

Medical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 58.7%\*, primarily driven by the benefit of market recovery from COVID-19 impacts and the associated deferral of medical procedures in the prior year across all of our businesses including Surgery, Orthopaedics, Vision and Interventional Solutions.

## **NOTABLE NEW ANNOUCEMENTS IN THE QUARTER:**

The information contained in this section should be read in conjunction with Johnson & Johnson's other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at [www.sec.gov](http://www.sec.gov), [www.jnj.com](http://www.jnj.com) or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases available online in the Investors section of the company's website at [news releases](#).

Regulatory Decisions	TECNIS SYNERGY and TECNIS SYNERGY TORIC II IOLS a Next Generation Treatment for Cataract Patients Received Regulatory Approval and Launched in the U.S. and Canada	<a href="#">(press release)</a>
		<a href="#">(press release)</a>
	RYBREVANT (amivantamab-vmjw) Receives U.S. FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations	<a href="#">(press release)</a>
	PONVORY (ponesimod) receives European Commission approval for the Treatment of Adults with Relapsing Forms of Multiple Sclerosis with Active Disease Defined by Clinical or Imaging Features	<a href="#">(press release)</a>
	DARZALEX (daratumumab) Subcutaneous (SC) Formulation Becomes the First Approved Treatment for Newly Diagnosed Systemic Light Chain Amyloidosis in Europe and Gains an Additional Approval in Pre-Treated Multiple Myeloma	<a href="#">(press release)</a>
	DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) Receives U.S. FDA Approval for Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse <sup>1</sup>	<a href="#">(press release)</a>
Regulatory Submissions	Janssen granted Breakthrough Therapy Designation from the U.S. FDA for Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma	<a href="#">(press release)</a>
	Janssen Submits Marketing Authorisation Application to the European Medicines Agency for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma	<a href="#">(press release)</a>
	Janssen Submits New Drug Application to U.S. FDA for XARELTO (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients	<a href="#">(press release)</a>
Other	Johnson & Johnson Joins World Health Organization in Efforts to Prevent Spread of Ebola in West Africa	<a href="#">(press release)</a>
	Janssen Discontinues Collaboration and License Agreement with argenx for Cusatuzumab	<a href="#">(press release)</a>
	ETHICON expands Advanced Bipolar Energy Portfolio with Launch of ENSEAL X1 Curved Jaw Tissue Sealer	<a href="#">(press release)</a>
	Johnson & Johnson Announces Positive New Data for the Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response	<a href="#">(press release)</a>
	Johnson & Johnson Consumer Inc. Issues Voluntary Recall of Specific NEUTROGENA and AVEENO Aerosol Sunscreen Products Due to the Presence of Benzene <sup>1</sup>	<a href="#">(press release)</a>

<sup>1</sup>Subsequent to the quarter

## **FULL-YEAR 2021 GUIDANCE:**

Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.

(\$ in Billions, except EPS)	April 2021	July 2021 (Base Business)	July 2021 (incl. COVID Vx)
Adjusted Operational Sales <sup>1,2</sup> Change vs. Prior Year	8.7% - 9.9%	9.5% - 10.5%	12.5% - 13.5%
Operational Sales <sup>2</sup> Change vs. Prior Year	\$89.3B - \$90.3B 8.2% - 9.4%	\$90.0B - \$90.8B 9.0% - 10.0%	\$92.5B - \$93.3B 12.0% - 13.0%
Estimated Reported Sales <sup>3</sup> Change vs. Prior Year	\$90.6B - \$91.6B 9.7% - 10.9%	\$91.3B - \$92.1B 10.5% - 11.5%	\$93.8B - \$94.6B 13.5% - 14.5%
Adjusted Operational EPS (Diluted) <sup>2,4</sup> Change vs. Prior Year	\$9.30 - \$9.45 15.8% - 17.7%		\$9.50 - \$9.60 18.4% - 19.6%
Adjusted EPS (Diluted) <sup>3,4</sup> Change vs. Prior Year	\$9.42 - \$9.57 17.3% - 19.2%		\$9.60 - \$9.70 19.6% - 20.8%

<sup>1</sup> [Non-GAAP financial measure](#); excludes the net impact of acquisitions and divestitures

<sup>2</sup> [Non-GAAP financial measure](#); excludes the impact of translational currency

<sup>3</sup> Calculated using Euro Average Rate: April 2021 = \$1.19 and July 2021 = \$1.19 (Illustrative purposes only)

<sup>4</sup> [Non-GAAP financial measure](#); excludes intangible amortization expense and special items

Note: % may have been rounded

Other modeling considerations will be provided on the [webcast](#).

## **WEBCAST INFORMATION:**

Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the [Johnson & Johnson website](#). A replay and podcast will be available approximately two hours after the live webcast in the Investors section of the company's website at [events-and-presentations](#).

## **ABOUT JOHNSON & JOHNSON:**

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

## **NON-GAAP FINANCIAL MEASURES:**

\*Operational sales growth excluding the impact of translational currency, adjusted operational sales growth excluding the net impact of acquisitions and divestitures and translational currency, as well as adjusted net earnings, adjusted diluted earnings per share and adjusted operational diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investors section of the company's website at [quarterly-results](#).

Copies of the financial schedules accompanying this earnings release are available on the company's website at [quarterly-results](#). These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, a [pharmaceutical pipeline](#) of selected compounds in late stage development and a copy of today's earnings call presentation can also be found in the Investors section of the company's website at [quarterly-results](#).

## **NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS:**

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the Company's ability to execute business continuity plans, as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent

in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021 including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," in the Company's most recently filed Quarterly Report on Form 10-Q and the Company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at [www.sec.gov](http://www.sec.gov), [www.jnj.com](http://www.jnj.com) or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

**Press Contacts:**

Christina Chan      Courtney Dugan  
(732) 524-6297      (347) 452-1061

**Investor Contacts:**

Christopher DeOrefice      Jennifer McIntyre  
(732) 524-2955      (732) 524-3922

**Johnson & Johnson and Subsidiaries**
**Supplementary Sales Data**

(Unaudited; Dollars in Millions)

	SECOND QUARTER						SIX MONTHS					
			Total	Percent Change		Currency			Total	Percent Change		Currency
	2021	2020		Operations			2021	2020		Operations		
<b>Sales to customers by segment of business</b>												
Consumer Health												
U.S.	\$ 1,751	1,557	12.4 %	12.4	-	\$ 3,362	3,297	2.0 %	2.0	-		
International	1,984	1,739	14.1	6.3	7.8	3,916	3,624	8.1	3.3	4.8		
	<b>3,735</b>	<b>3,296</b>	13.3	9.2	4.1	<b>7,278</b>	<b>6,921</b>	5.2	2.7	2.5		
Pharmaceutical												
U.S.	6,869	6,120	12.2	12.2	-	13,315	12,181	9.3	9.3	-		
International	5,730	4,632	23.7	15.4	8.3	11,483	9,705	18.3	11.4	6.9		
	<b>12,599</b>	<b>10,752</b>	17.2	13.6	3.6	<b>24,798</b>	<b>21,886</b>	13.3	10.3	3.0		
Medical Devices												
U.S.	3,299	1,862	77.2	77.2	-	6,353	4,760	33.5	33.5	-		
International	3,679	2,426	51.6	41.9	9.7	7,204	5,460	31.9	24.5	7.4		
	<b>6,978</b>	<b>4,288</b>	62.7	57.2	5.5	<b>13,557</b>	<b>10,220</b>	32.7	28.7	4.0		
U.S.	11,919	9,539	24.9	24.9	-	23,030	20,238	13.8	13.8	-		
International	11,393	8,797	29.5	20.9	8.6	22,603	18,789	20.3	13.7	6.6		
Worldwide	<b>\$ 23,312</b>	<b>18,336</b>	27.1 %	23.0	4.1	<b>\$ 45,633</b>	<b>39,027</b>	16.9 %	13.7	3.2		

**Note:** Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.



**Johnson & Johnson and Subsidiaries**  
**Supplementary Sales Data**

(Unaudited; Dollars in Millions)

	SECOND QUARTER				
	2021	2020	Total	Percent Change	
				Operations	Currency
<b>Sales to customers by geographic area</b>					
U.S.	\$ 11,919	9,539	24.9 %	24.9	-
Europe	5,668	4,063	39.5	28.6	10.9
Western Hemisphere excluding U.S.	1,367	1,133	20.6	12.7	7.9
Asia-Pacific, Africa	4,358	3,601	21.0	14.8	6.2
International	11,393	8,797	29.5	20.9	8.6
Worldwide	\$ 23,312	18,336	27.1 %	23.0	4.1

	SIX MONTHS				
	2021	2020	Total	Percent Change	
				Operations	Currency
	\$ 23,030	20,238	13.8 %	13.8	-
	11,082	8,890	24.7	15.6	9.1
	2,791	2,635	5.9	5.4	0.5
	8,730	7,264	20.2	14.2	6.0
	22,603	18,789	20.3	13.7	6.6
	\$ 45,633	39,027	16.9 %	13.7	3.2

**Note:** Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)

SECOND QUARTER

	2021		2020		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$ 23,312	100.0	\$ 18,336	100.0	27.1
Cost of products sold	7,587	32.5	6,579	35.9	15.3
Gross Profit	15,725	67.5	11,757	64.1	33.8
Selling, marketing and administrative expenses	6,073	26.1	4,993	27.2	21.6
Research and development expense	3,394	14.6	2,707	14.8	25.4
In-process research and development	0	0.0	6	0.0	
Interest (income) expense, net	28	0.1	26	0.2	
Other (income) expense, net	(488)	(2.1)	24	0.1	
Restructuring	56	0.2	61	0.3	
Earnings before provision for taxes on income	6,662	28.6	3,940	21.5	69.1
Provision for taxes on income	384	1.7	314	1.7	22.3
Net earnings	\$ 6,278	26.9	\$ 3,626	19.8	73.1
Net earnings per share (Diluted)	\$ 2.35		\$ 1.36		72.8
Average shares outstanding (Diluted)	2,671.6		2,665.5		
Effective tax rate	5.8 %		8.0 %		
<b>Adjusted earnings before provision for taxes and net earnings <sup>(1)</sup></b>					
Earnings before provision for taxes on income	\$ 7,776	33.4	\$ 5,337	29.1	45.7
Net earnings	\$ 6,625	28.4	\$ 4,446	24.2	49.0
Net earnings per share (Diluted)	\$ 2.48		\$ 1.67		48.5
Effective tax rate	14.8 %		16.7 %		

<sup>(1)</sup> See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)

SIX MONTHS

	2021		2020		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$ 45,633	100.0	\$ 39,027	100.0	16.9
Cost of products sold	14,650	32.1	13,641	35.0	7.4
Gross Profit	30,983	67.9	25,386	65.0	22.0
Selling, marketing and administrative expenses	11,505	25.2	10,196	26.1	12.8
Research and development expense	6,572	14.4	5,287	13.5	24.3
In-process research and development	0	0.0	6	0.0	
Interest (income) expense, net	76	0.2	(16)	0.0	
Other (income) expense, net	(1,370)	(3.0)	(655)	(1.7)	
Restructuring	109	0.2	119	0.3	
Earnings before provision for taxes on income	14,091	30.9	10,449	26.8	34.9
Provision for taxes on income	1,616	3.6	1,027	2.7	57.4
Net earnings	\$ 12,475	27.3	\$ 9,422	24.1	32.4
Net earnings per share (Diluted)	\$ 4.67		\$ 3.53		32.3
Average shares outstanding (Diluted)	2,674.0		2,671.0		
Effective tax rate	11.5 %		9.8 %		
<b>Adjusted earnings before provision for taxes and net earnings <sup>(1)</sup></b>					
Earnings before provision for taxes on income	\$ 16,067	35.2	\$ 12,581	32.2	27.7
Net earnings	\$ 13,549	29.7	\$ 10,600	27.2	27.8
Net earnings per share (Diluted)	\$ 5.07		\$ 3.97		27.7
Effective tax rate	15.7 %		15.7 %		

<sup>(1)</sup> See Reconciliation of Non-GAAP Financial Measures.

**Johnson & Johnson and Subsidiaries**

**Reconciliation of Non-GAAP Financial Measures**

	Second Quarter		Six Months Ended	
(Dollars in Millions Except Per Share Data)	2021	2020	2021	2020
Net Earnings, after tax- as reported	\$6,278	\$3,626	\$12,475	\$9,422
<i>Pre-tax Adjustments</i>				
Intangible Asset Amortization expense	1,202	1,127	2,417	2,245
Litigation related	(23)	613	(23)	733
IPR&D	-	6	-	6
Restructuring related	108	115	212	233
Acquisition, integration and divestiture related <sup>1</sup>	14	29	(524)	(933)
Unrealized (gains)/losses on securities	(243)	(533)	(208)	(206)
Medical Device Regulation	56	37	102	51
Other	-	3	-	3
<i>Tax Adjustments</i>				
Tax impact on special item adjustments <sup>2</sup>	(135)	(253)	(248)	(520)
Tax legislation and other tax related	(632)	(324)	(654)	(434)
Adjusted Net Earnings, after tax	<b>\$6,625</b>	<b>\$4,446</b>	<b>\$13,549</b>	<b>\$10,600</b>
Average shares outstanding (Diluted)	2,671.6	2,665.5	2,674.0	2,671.0
Adjusted net earnings per share (Diluted)	<b>\$2.48</b>	<b>\$1.67</b>	<b>\$5.07</b>	<b>\$3.97</b>
Operational adjusted net earnings per share (Diluted)	<b>\$2.42</b>		<b>\$4.91</b>	

**Notes:**

<sup>1</sup> Acquisition, integration and divestiture related for the six months of 2021 primarily includes the gain on the divestiture of two Pharmaceutical brands outside of the U.S. The six months of 2020 primarily includes a \$983M Contingent Consideration reversal related to the timing of certain developmental milestones associated with the Auris Health acquisition.

<sup>2</sup> The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

Johnson & Johnson and Subsidiaries  
Reconciliation of Non-GAAP Financial Measure

Adjusted Operational Sales Growth  
SECOND QUARTER 2021 ACTUAL vs. 2020 ACTUAL

<u>Segments</u>				
	<u>Consumer Health</u>	<u>Pharmaceutical</u>	<u>Medical Devices</u>	<u>Total</u>
<b>WW As Reported</b>	<b>13.3%</b>	<b>17.2%</b>	<b>62.7%</b>	<b>27.1%</b>
U.S.	12.4%	12.2%	77.2%	24.9%
International	14.1%	23.7%	51.6%	29.5%
<b>WW Currency</b>	<b>4.1</b>	<b>3.6</b>	<b>5.5</b>	<b>4.1</b>
U.S.	-	-	-	-
International	7.8	8.3	9.7	8.6
<b>WW Operational</b>	<b>9.2%</b>	<b>13.6%</b>	<b>57.2%</b>	<b>23.0%</b>
U.S.	12.4%	12.2%	77.2%	24.9%
International	6.3%	15.4%	41.9%	20.9%
<b>General Surgery</b>				
<b>Advanced Sterilization Products</b>			<b>1.2</b>	<b>0.2</b>
U.S.			0.0	0.0
International			1.9	0.4
<b>All Other Acquisitions and Divestitures</b>	<b>0.8</b>	<b>0.6</b>	<b>0.3</b>	<b>0.6</b>
U.S.	0.6	(0.1)	0.7	0.1
International	1.1	1.5	0.0	1.0
<b>WW Adjusted Operational</b>	<b>10.0%</b>	<b>14.1%</b>	<b>58.7%</b>	<b>23.8%</b>
U.S.	13.0%	12.1%	77.9%	25.1%
International	7.4%	16.8%	43.8%	22.4%

Note: Percentages are based on actual, non-rounded figures and may not sum

Johnson & Johnson and Subsidiaries  
Reconciliation of Non-GAAP Financial Measure

Adjusted Operational Sales Growth  
SIX MONTHS 2021 ACTUAL vs. 2020 ACTUAL

	Segments			
	Consumer Health	Pharmaceutical	Medical Devices	Total
<b>WW As Reported</b>	<b>5.2%</b>	<b>13.3%</b>	<b>32.7%</b>	<b>16.9%</b>
U.S.	2.0%	9.3%	33.5%	13.8%
International	8.1%	18.3%	31.9%	20.3%
<b>WW Currency</b>	<b>2.5</b>	<b>3.0</b>	<b>4.0</b>	<b>3.2</b>
U.S.	-	-	-	-
International	4.8	6.9	7.4	6.6
<b>WW Operational</b>	<b>2.7%</b>	<b>10.3%</b>	<b>28.7%</b>	<b>13.7%</b>
U.S.	2.0%	9.3%	33.5%	13.8%
International	3.3%	11.4%	24.5%	13.7%
<b>General Surgery</b>				
<b>Advanced Sterilization Products</b>			<b>0.8</b>	<b>0.2</b>
U.S.			0.0	0.0
International			1.5	0.4
<b>All Other Acquisitions and Divestitures</b>	<b>0.6</b>	<b>0.5</b>	<b>0.2</b>	<b>0.4</b>
U.S.	0.5	(0.1)	0.5	0.1
International	0.7	1.2	0.0	0.8
<b>WW Adjusted Operational</b>	<b>3.3%</b>	<b>10.7%</b>	<b>29.7%</b>	<b>14.4%</b>
U.S.	2.5%	9.2%	33.9%	13.9%
International	4.0%	12.6%	26.0%	14.8%

**Note:** Percentages are based on actual, non-rounded figures and may not sum



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	SECOND QUARTER		% Change		
	2021	2020	Reported	Operational <sup>(1)</sup>	Currency
<b>CONSUMER HEALTH SEGMENT <sup>(2)</sup></b>					
<u>OTC</u>					
US	\$ 675	627	7.7%	7.7%	-
Intl	633	522	21.2%	10.4%	10.8%
WW	1,307	1,149	13.8%	8.9%	4.9%
<u>SKIN HEALTH / BEAUTY</u>					
US	659	536	23.0%	23.0%	-
Intl	511	471	8.4%	1.4%	7.0%
WW	1,170	1,007	16.2%	12.9%	3.3%
<u>ORAL CARE</u>					
US	165	170	-3.1%	-3.1%	-
Intl	260	227	14.6%	6.7%	7.9%
WW	426	397	7.0%	2.5%	4.5%
<u>BABY CARE</u>					
US	97	96	0.8%	0.8%	-
Intl	290	260	11.5%	6.6%	4.9%
WW	387	356	8.6%	5.0%	3.6%
<u>WOMEN'S HEALTH</u>					
US	3	3	-3.1%	-3.1%	-
Intl	227	199	14.2%	9.2%	5.0%
WW	230	202	13.9%	9.0%	4.9%
<u>WOUND CARE / OTHER</u>					
US	153	126	20.9%	20.9%	-
Intl	64	59	7.3%	-2.8%	10.1%
WW	216	185	16.6%	13.4%	3.2%
<b>TOTAL CONSUMER HEALTH</b>					
US	1,751	1,557	12.4%	12.4%	-
Intl	1,984	1,739	14.1%	6.3%	7.8%
WW	\$ 3,735	3,296	13.3%	9.2%	4.1%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	SIX MONTHS		% Change		
	2021	2020	Reported	Operational <sup>(1)</sup>	Currency
	\$ 1,274	1,316	-3.2%	-3.2%	-
	1,208	1,181	2.3%	-4.7%	7.0%
	2,482	2,497	-0.6%	-3.9%	3.3%
	1,293	1,195	8.2%	8.2%	-
	1,040	929	12.0%	6.8%	5.2%
	2,333	2,124	9.8%	7.6%	2.2%
	328	346	-5.2%	-5.2%	-
	514	446	15.3%	10.2%	5.1%
	843	792	6.3%	3.5%	2.8%
	193	188	2.4%	2.4%	-
	583	529	10.2%	9.0%	1.2%
	776	717	8.1%	7.3%	0.8%
	6	7	-16.0%	-16.0%	-
	446	427	4.5%	3.1%	1.4%
	452	434	4.2%	2.8%	1.4%
	268	245	9.3%	9.3%	-
	125	111	12.1%	5.2%	6.9%
	393	356	10.2%	8.0%	2.2%
	3,362	3,297	2.0%	2.0%	-
	3,916	3,624	8.1%	3.3%	4.8%
	\$ 7,278	6,921	5.2%	2.7%	2.5%

See footnotes at end of schedule

PHARMACEUTICAL SEGMENT <sup>(2,3)</sup>	REPORTED SALES vs. PRIOR PERIOD (\$MM)					REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	SECOND QUARTER					SIX MONTHS				
	2021	2020	Reported	% Change Operational <sup>(1)</sup>	Currency	2021	2020	Reported	% Change Operational <sup>(1)</sup>	Currency
<b>IMMUNOLOGY</b>										
US	\$ 2,748	2,362	16.4%	16.4%	-	\$ 5,161	4,772	8.2%	8.2%	-
Intl	1,483	1,161	27.7%	18.2%	9.5%	2,984	2,389	24.9%	17.0%	7.9%
WW	4,231	3,523	20.1%	17.0%	3.1%	8,145	7,161	13.7%	11.1%	2.6%
<b>REMICADE</b>										
US	540	593	-9.1%	-9.1%	-	1,029	1,218	-15.6%	-15.6%	-
US Exports <sup>(4)</sup>	93	133	-30.0%	-30.0%	-	150	243	-38.2%	-38.2%	-
Intl	255	208	22.4%	11.1%	11.3%	487	464	4.9%	-1.7%	6.6%
WW	888	935	-5.1%	-7.6%	2.5%	1,665	1,925	-13.5%	-15.1%	1.6%
<b>SIMPONI / SIMPONI ARIA</b>										
US	290	256	12.8%	12.8%	-	545	528	3.2%	3.2%	-
Intl	294	289	1.7%	-3.8%	5.5%	601	547	9.8%	4.5%	5.3%
WW	584	546	6.9%	4.0%	2.9%	1,146	1,075	6.6%	3.8%	2.8%
<b>STELARA</b>										
US	1,496	1,138	31.4%	31.4%	-	2,827	2,355	20.0%	20.0%	-
Intl	778	558	39.2%	28.6%	10.6%	1,595	1,161	37.3%	28.1%	9.2%
WW	2,274	1,697	34.0%	30.5%	3.5%	4,422	3,516	25.8%	22.7%	3.1%
<b>TREMFYA</b>										
US	325	241	35.0%	35.0%	-	599	428	40.0%	40.0%	-
Intl	155	101	52.3%	41.1%	11.2%	298	210	41.8%	31.8%	10.0%
WW	479	342	40.2%	36.8%	3.4%	897	638	40.6%	37.3%	3.3%
<b>OTHER IMMUNOLOGY</b>										
US	5	-	*	*	-	12	-	*	*	-
Intl	1	3	-61.3%	-67.9%	6.6%	3	6	-51.2%	-53.9%	2.7%
WW	7	3	*	*	*	15	6	*	*	*
<b>INFECTIOUS DISEASES</b>										
US	444	416	6.8%	6.8%	-	956	852	12.2%	12.2%	-
Intl	585	463	26.3%	18.2%	8.1%	1,079	946	14.1%	7.8%	6.3%
WW	1,028	878	17.1%	12.8%	4.3%	2,035	1,798	13.2%	9.9%	3.3%
<b>COVID-19 VACCINE</b>										
US	51	-	*	*	-	151	-	*	*	-
Intl	113	-	*	*	-	113	-	*	*	-
WW	164	-	*	*	-	264	-	*	*	-
<b>EDURANT / rilpivirine</b>										
US	9	10	-9.3%	-9.3%	-	19	22	-10.9%	-10.9%	-
Intl	253	246	2.8%	-4.0%	6.8%	486	458	6.0%	-1.7%	7.7%
WW	262	256	2.3%	-4.2%	6.5%	505	480	5.2%	-2.1%	7.3%
<b>PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA</b>										
US	368	379	-3.2%	-3.2%	-	748	775	-3.5%	-3.5%	-
Intl	137	130	5.5%	-5.9%	11.4%	303	314	-3.5%	-8.5%	5.0%
WW	505	510	-1.0%	-3.9%	2.9%	1,051	1,089	-3.5%	-5.0%	1.5%
<b>OTHER INFECTIOUS DISEASES</b>										
US	16	25	-36.2%	-36.2%	-	37	54	-31.3%	-31.3%	-
Intl	81	87	-6.2%	-13.4%	7.2%	177	174	1.8%	-3.0%	4.8%
WW	98	113	-13.0%	-18.5%	5.5%	215	229	-6.1%	-9.7%	3.6%



REPORTED SALES vs. PRIOR PERIOD (\$MM)

SECOND QUARTER

NEUROSCIENCE

	2021	2020	% Change		
			Reported	Operational <sup>(1)</sup>	Currency
US	842	778	8.0%	8.0%	-
Intl	967	809	19.6%	13.1%	6.5%
WW	1,808	1,587	13.9%	10.6%	3.3%
<u>CONCERTA / Methylphenidate</u>					
US	35	55	-36.0%	-36.0%	-
Intl	127	94	33.7%	25.6%	8.1%
WW	161	149	8.1%	3.0%	5.1%
<u>INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</u>					
US	645	576	11.9%	11.9%	-
Intl	380	303	25.1%	15.9%	9.2%
WW	1,024	879	16.4%	13.3%	3.1%
<u>RISPERDAL CONSTA</u>					
US	72	74	-3.0%	-3.0%	-
Intl	84	79	6.4%	0.2%	6.2%
WW	155	153	1.9%	-1.3%	3.2%
<u>OTHER NEUROSCIENCE</u>					
US	91	75	20.9%	20.9%	-
Intl	377	331	13.8%	10.0%	3.8%
WW	468	406	15.1%	12.0%	3.1%
<u>ONCOLOGY</u>					
US	1,462	1,181	23.7%	23.7%	-
Intl	2,073	1,609	28.8%	19.8%	9.0%
WW	3,535	2,791	26.7%	21.5%	5.2%
<u>DARZALEX</u>					
US	770	492	56.7%	56.7%	-
Intl	663	409	62.1%	50.3%	11.8%
WW	1,433	901	59.2%	53.8%	5.4%
<u>ERLEADA</u>					
US	193	136	41.5%	41.5%	-
Intl	109	33	*	*	*
WW	302	170	77.6%	73.7%	3.9%
<u>IMBRUVICA</u>					
US	454	447	1.7%	1.7%	-
Intl	662	502	31.9%	22.1%	9.8%
WW	1,116	949	17.7%	12.5%	5.2%
<u>ZYTIGA / abiraterone acetate</u>					
US	21	87	-75.3%	-75.3%	-
Intl	542	480	12.8%	5.4%	7.4%
WW	563	568	-0.8%	-7.1%	6.3%
<u>OTHER ONCOLOGY</u>					
US	23	20	18.8%	18.8%	-
Intl	97	185	-47.2%	-49.6%	2.4%
WW	120	204	-40.9%	-43.0%	2.1%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

SIX MONTHS

	2021	2020	% Change		
			Reported	Operational <sup>(1)</sup>	Currency
US	1,613	1,526	5.6%	5.6%	-
Intl	1,916	1,719	11.5%	6.3%	5.2%
WW	3,529	3,245	8.7%	6.0%	2.7%
<u>CONCERTA / Methylphenidate</u>					
US	82	107	-23.1%	-23.1%	-
Intl	250	212	17.5%	11.1%	6.4%
WW	332	320	3.9%	-0.3%	4.2%
<u>INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</u>					
US	1,234	1,120	10.2%	10.2%	-
Intl	756	642	17.7%	9.9%	7.8%
WW	1,989	1,762	12.9%	10.1%	2.8%
<u>RISPERDAL CONSTA</u>					
US	139	150	-7.5%	-7.5%	-
Intl	173	173	0.4%	-4.6%	5.0%
WW	312	323	-3.3%	-6.0%	2.7%
<u>OTHER NEUROSCIENCE</u>					
US	158	150	5.6%	5.6%	-
Intl	738	691	6.7%	4.3%	2.4%
WW	896	841	6.5%	4.5%	2.0%
<u>ONCOLOGY</u>					
US	2,839	2,356	20.5%	20.5%	-
Intl	4,266	3,448	23.7%	16.2%	7.5%
WW	7,105	5,804	22.4%	17.9%	4.5%
<u>DARZALEX</u>					
US	1,461	955	53.1%	53.1%	-
Intl	1,337	883	51.4%	42.3%	9.1%
WW	2,798	1,838	52.2%	47.9%	4.3%
<u>ERLEADA</u>					
US	364	255	42.7%	42.7%	-
Intl	199	57	*	*	*
WW	563	313	80.0%	76.4%	3.6%
<u>IMBRUVICA</u>					
US	898	879	2.2%	2.2%	-
Intl	1,342	1,101	21.9%	14.2%	7.7%
WW	2,241	1,980	13.2%	8.9%	4.3%
<u>ZYTIGA / abiraterone acetate</u>					
US	71	226	-68.5%	-68.5%	-
Intl	1,130	1,032	9.5%	2.5%	7.0%
WW	1,201	1,258	-4.5%	-10.3%	5.8%
<u>OTHER ONCOLOGY</u>					
US	44	42	6.3%	6.3%	-
Intl	258	375	-31.0%	-34.3%	3.3%
WW	302	416	-27.3%	-30.2%	2.9%

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**  
**SECOND QUARTER**

**PULMONARY HYPERTENSION**

			% Change		
	2021	2020	Reported	Operational <sup>(1)</sup>	Currency
US	595	545	9.0%	9.0%	-
Intl	275	243	13.5%	7.9%	5.6%
WW	<u>870</u>	<u>789</u>	10.4%	8.7%	1.7%
<b><u>OPSUMIT</u></b>					
US	290	256	13.6%	13.6%	-
Intl	172	150	14.9%	9.0%	5.9%
WW	<u>463</u>	<u>406</u>	14.1%	11.9%	2.2%
<b><u>UPTRAVI</u></b>					
US	268	254	6.0%	6.0%	-
Intl	45	28	54.9%	42.9%	12.0%
WW	<u>313</u>	<u>282</u>	11.0%	9.8%	1.2%
<b><u>OTHER PULMONARY HYPERTENSION</u></b>					
US	36	37	-2.4%	-2.4%	-
Intl	59	64	-8.2%	-10.3%	2.1%
WW	<u>95</u>	<u>101</u>	-6.1%	-7.5%	1.4%
<b><u>CARDIOVASCULAR / METABOLISM / OTHER</u></b>					
US	780	837	-6.9%	-6.9%	-
Intl	346	347	-0.3%	-8.4%	8.1%
WW	<u>1,126</u>	<u>1,184</u>	-5.0%	-7.3%	2.3%
<b><u>XARELTO</u></b>					
US	569	559	1.8%	1.8%	-
Intl	-	-	-	-	-
WW	<u>569</u>	<u>559</u>	1.8%	1.8%	-
<b><u>INVOKANA / INVOKAMET</u></b>					
US	96	132	-27.0%	-27.0%	-
Intl	64	47	33.8%	22.1%	11.7%
WW	<u>160</u>	<u>179</u>	-10.9%	-14.0%	3.1%
<b><u>PROCRIT / EPREX</u></b>					
US	59	70	-16.3%	-16.3%	-
Intl	69	66	3.7%	-4.5%	8.2%
WW	<u>127</u>	<u>136</u>	-6.6%	-10.6%	4.0%
<b><u>OTHER</u></b>					
US	57	78	-26.7%	-26.7%	-
Intl	214	234	-8.4%	-15.7%	7.3%
WW	<u>271</u>	<u>312</u>	-13.0%	-18.4%	5.4%
<b><u>TOTAL PHARMACEUTICAL</u></b>					
US	6,869	6,120	12.2%	12.2%	-
Intl	5,730	4,632	23.7%	15.4%	8.3%
WW	<u>\$ 12,599</u>	<u>10,752</u>	17.2%	13.6%	3.6%

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**  
**SIX MONTHS**

			% Change		
	2021	2020	Reported	Operational <sup>(1)</sup>	Currency
	1,168	1,031	13.2%	13.2%	-
	563	503	12.1%	6.7%	5.4%
	<u>1,731</u>	<u>1,534</u>	12.9%	11.1%	1.8%
	562	485	15.9%	15.9%	-
	351	310	13.1%	7.6%	5.5%
	<u>913</u>	<u>795</u>	14.8%	12.7%	2.1%
	527	466	13.3%	13.3%	-
	91	66	36.8%	27.4%	9.4%
	<u>618</u>	<u>532</u>	16.2%	15.0%	1.2%
	78	81	-3.0%	-3.0%	-
	122	126	-3.5%	-6.3%	2.8%
	<u>200</u>	<u>207</u>	-3.3%	-5.0%	1.7%
	1,579	1,643	-3.9%	-3.9%	-
	674	701	-3.8%	-9.9%	6.1%
	<u>2,253</u>	<u>2,344</u>	-3.9%	-5.7%	1.8%
	1,158	1,086	6.6%	6.6%	-
	-	-	-	-	-
	<u>1,158</u>	<u>1,086</u>	6.6%	6.6%	-
	183	249	-26.6%	-26.6%	-
	127	105	20.3%	12.2%	8.1%
	<u>310</u>	<u>354</u>	-12.6%	-15.0%	2.4%
	121	146	-17.3%	-17.3%	-
	133	145	-8.2%	-14.1%	5.9%
	<u>254</u>	<u>291</u>	-12.8%	-15.7%	2.9%
	117	163	-27.8%	-27.8%	-
	415	451	-8.1%	-13.7%	5.6%
	<u>532</u>	<u>614</u>	-13.3%	-17.4%	4.1%
	13,315	12,181	9.3%	9.3%	-
	11,483	9,705	18.3%	11.4%	6.9%
	<u>\$ 24,798</u>	<u>21,886</u>	13.3%	10.3%	3.0%

See footnotes at end of schedule

**MEDICAL DEVICES SEGMENT <sup>(2)</sup>**

**INTERVENTIONAL SOLUTIONS**

	2021		2020		% Change		Currency
	2021	2020	Reported	Operational <sup>(1)</sup>	Reported	Operational <sup>(1)</sup>	
US	\$ 475	255	86.5%	86.5%	-	-	-
Intl	572	335	70.5%	59.8%	10.7%	10.7%	10.7%
WW	1,046	590	77.4%	71.3%	6.1%	6.1%	6.1%

**ORTHOPAEDICS**

	2021		2020		% Change		Currency
	2021	2020	Reported	Operational <sup>(1)</sup>	Reported	Operational <sup>(1)</sup>	
US	1,323	869	52.3%	52.3%	-	-	-
Intl	904	583	55.1%	43.2%	11.9%	11.9%	11.9%
WW	2,227	1,451	53.4%	48.6%	4.8%	4.8%	4.8%

**HIPS**

	2021		2020		% Change		Currency
	2021	2020	Reported	Operational <sup>(1)</sup>	Reported	Operational <sup>(1)</sup>	
US	234	137	70.5%	70.5%	-	-	-
Intl	159	88	78.6%	64.3%	14.3%	14.3%	14.3%
WW	392	226	73.7%	68.1%	5.6%	5.6%	5.6%

**KNEES**

	2021		2020		% Change		Currency
	2021	2020	Reported	Operational <sup>(1)</sup>	Reported	Operational <sup>(1)</sup>	
US	210	108	94.3%	94.3%	-	-	-
Intl	140	66	*	95.1%	16.8%	16.8%	16.8%
WW	350	174	*	94.6%	6.4%	6.4%	6.4%

**TRAUMA**

	2021		2020		% Change		Currency
	2021	2020	Reported	Operational <sup>(1)</sup>	Reported	Operational <sup>(1)</sup>	
US	447	354	26.0%	26.0%	-	-	-
Intl	263	198	32.7%	22.7%	10.0%	10.0%	10.0%
WW	710	553	28.4%	24.8%	3.6%	3.6%	3.6%

**SPINE, SPORTS & OTHER**

	2021		2020		% Change		Currency
	2021	2020	Reported	Operational <sup>(1)</sup>	Reported	Operational <sup>(1)</sup>	
US	433	270	60.6%	60.6%	-	-	-
Intl	343	230	49.0%	37.9%	11.1%	11.1%	11.1%
WW	776	499	55.3%	50.2%	5.1%	5.1%	5.1%

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

		2021		2020		% Change		Currency
		2021	2020	Reported	Operational <sup>(1)</sup>	Reported	Operational <sup>(1)</sup>	
<b>INTERVENTIONAL SOLUTIONS</b>		909	620	46.7%	46.7%	-	-	-
		1,086	697	55.7%	46.4%	9.3%	9.3%	9.3%
<b>ORTHOPAEDICS</b>		1,995	1,317	51.5%	46.5%	5.0%	5.0%	5.0%
<b>HIPS</b>		2,572	2,119	21.4%	21.4%	-	-	-
		1,768	1,371	29.0%	20.2%	8.8%	8.8%	8.8%
<b>KNEES</b>		444	343	29.6%	29.6%	-	-	-
		305	220	38.3%	28.6%	9.7%	9.7%	9.7%
<b>TRAUMA</b>		749	563	33.0%	29.2%	3.8%	3.8%	3.8%
		395	322	22.7%	22.7%	-	-	-
		272	196	39.2%	29.5%	9.7%	9.7%	9.7%
<b>SPINE, SPORTS &amp; OTHER</b>		667	517	28.9%	25.2%	3.7%	3.7%	3.7%
		897	761	17.8%	17.8%	-	-	-
		545	445	22.5%	14.4%	8.1%	8.1%	8.1%
		1,443	1,207	19.6%	16.5%	3.1%	3.1%	3.1%
		836	693	20.7%	20.7%	-	-	-
		646	510	26.7%	18.0%	8.7%	8.7%	8.7%
		1,482	1,202	23.2%	19.6%	3.6%	3.6%	3.6%

REPORTED SALES vs. PRIOR PERIOD (\$MM)					
SECOND QUARTER					
	2021	2020	% Change		
			Reported	Operational <sup>(1)</sup>	Currency
<b>SURGERY</b>					
US	1,035	490	*	*	-
Intl	1,487	1,060	40.2%	30.6%	9.6%
WW	2,522	1,551	62.6%	56.0%	6.6%
<b>ADVANCED</b>					
US	459	277	65.4%	65.4%	-
Intl	708	498	42.2%	32.5%	9.7%
WW	1,168	775	50.5%	44.3%	6.2%
<b>GENERAL</b>					
US	576	213	*	*	-
Intl	779	562	38.5%	28.9%	9.6%
WW	1,354	775	74.7%	67.8%	6.9%
<b>VISION</b>					
US	467	248	88.3%	88.3%	-
Intl	716	447	60.0%	53.7%	6.3%
WW	1,183	695	70.1%	66.0%	4.1%
<b>CONTACT LENSES / OTHER</b>					
US	352	203	73.3%	73.3%	-
Intl	517	352	47.0%	41.9%	5.1%
WW	868	554	56.7%	53.4%	3.3%
<b>SURGICAL</b>					
US	115	45	*	*	-
Intl	199	96	*	97.1%	10.6%
WW	314	141	*	*	*
<b>TOTAL MEDICAL DEVICES</b>					
US	3,299	1,862	77.2%	77.2%	-
Intl	3,679	2,426	51.6%	41.9%	9.7%
WW	\$ 6,978	4,288	62.7%	57.2%	5.5%

REPORTED SALES vs. PRIOR PERIOD (\$MM)					
SIX MONTHS					
	2021	2020	% Change		
			Reported	Operational <sup>(1)</sup>	Currency
	1,933	1,334	44.9%	44.9%	-
	2,961	2,317	27.8%	20.4%	7.4%
	4,894	3,651	34.0%	29.3%	4.7%
	864	658	31.3%	31.3%	-
	1,421	1,065	33.4%	25.6%	7.8%
	2,286	1,723	32.6%	27.8%	4.8%
	1,069	676	58.1%	58.1%	-
	1,540	1,252	23.0%	15.9%	7.1%
	2,608	1,928	35.3%	30.7%	4.6%
	939	687	36.6%	36.6%	-
	1,389	1,075	29.2%	24.6%	4.6%
	2,328	1,762	32.1%	29.3%	2.8%
	723	549	31.6%	31.6%	-
	1,003	819	22.5%	18.5%	4.0%
	1,725	1,368	26.1%	23.7%	2.4%
	216	138	56.3%	56.3%	-
	386	256	50.9%	44.4%	6.5%
	602	394	52.8%	48.6%	4.2%
	6,353	4,760	33.5%	33.5%	-
	7,204	5,460	31.9%	24.5%	7.4%
	\$ 13,557	10,220	32.7%	28.7%	4.0%

**Note:** Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

\* Percentage greater than 100% or not meaningful

(1) Operational growth excludes the effect of translational currency

(2) Unaudited

(3) Certain prior year amounts have been reclassified to conform to current year product disclosures

(4) Reported as U.S. sales